Novo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember"
EVP Ludovic Helfgott firmly establishes that the Biopharm business is solidly linked with Novo Nordisk's future.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
It doesn't really fit.
The disease area is different, patient groups are significantly smaller, the production of drugs is completely different, and investors typically hate models with more businesses-in-one. Still, this is what it does.
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.